Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066636 · ClinicalTrials.gov registry record · Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,428
- Enrollment target
NCT02066636: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT02066636 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,428 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066636, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,428 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
Primary Outcome
A treatment related adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that has a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion r
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,428 participants |
| Start Date | 2014-04-09 |
| Est. Completion | 2021-10-06 |
| Phase | Phase 3 |
What the finished NCT02066636 record still lists
NCT02066636 is an interventional study that assigns participants to a tested intervention. Its 1,428 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% higher).
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02066636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02066636 about?
NCT02066636 is a clinical study titled "A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen". The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
What is the current status of trial NCT02066636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,428 participants. The study started on 2014-04-09. Estimated completion is 2021-10-06.
What interventions are being tested in trial NCT02066636?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02066636?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02066636's enrollment target sits among peer trials
1,428 169th of 2000 higher than 1,832 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI